At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Miguel Perales, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to reduce graft-versus-host disease (GvHD), highlighting ex vivo T-cell depletion. An ablative conditioning regimen combined with ex vivo T-cell depletion using CD34 selection offers long-term survival in patients with significantly reduced acute and chronic GvHD and low risk of relapse in acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates